Literature DB >> 25691160

JMML and RALD (Ras-associated autoimmune leukoproliferative disorder): common genetic etiology yet clinically distinct entities.

Katherine R Calvo1, Susan Price2, Raul C Braylan1, Joao Bosco Oliveira3, Michael Lenardo2, Thomas A Fleisher1, V Koneti Rao2.   

Abstract

Ras-associated autoimmune leukoproliferative disorder (RALD) is a chronic, nonmalignant condition that presents with persistent monocytosis and is often associated with leukocytosis, lymphoproliferation, and autoimmune phenomena. RALD has clinical and laboratory features that overlap with those of juvenile myelomonocytic leukemia (JMML) and chronic myelomonocytic leukemia (CMML), including identical somatic mutations in KRAS or NRAS genes noted in peripheral blood mononuclear cells. Long-term follow-up of these patients suggests that RALD has an indolent clinical course whereas JMML is fatal if left untreated. Immunophenotyping peripheral blood from RALD patients shows characteristic circulating activated monocytes and polyclonal CD10(+) B cells. Distinguishing RALD from JMML and CMML has implications for clinical care and prognosis.

Entities:  

Mesh:

Year:  2015        PMID: 25691160      PMCID: PMC4424627          DOI: 10.1182/blood-2014-11-567917

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  39 in total

1.  Long-term haematological improvement after non-intensive or no chemotherapy in juvenile myelomonocytic leukaemia and poor correlation with adult myelodysplasia spliceosome-related mutations.

Authors:  Kazuyuki Matsuda; Nao Yoshida; Shuhei Miura; Yozo Nakazawa; Kazuo Sakashita; Nobuyuki Hyakuna; Masahiro Saito; Fumiyo Kato; Atsushi Ogawa; Akihiro Watanabe; Manabu Sotomatsu; Chie Kobayashi; Toshiro Ito; Fumihiro Ishida; Atsushi Manabe; Seiji Kojima; Kenichi Koike
Journal:  Br J Haematol       Date:  2012-02-20       Impact factor: 6.998

Review 2.  Chronic myelomonocytic leukemia in childhood: a retrospective analysis of 110 cases. European Working Group on Myelodysplastic Syndromes in Childhood (EWOG-MDS)

Authors:  C M Niemeyer; M Arico; G Basso; A Biondi; A Cantu Rajnoldi; U Creutzig; O Haas; J Harbott; H Hasle; G Kerndrup; F Locatelli; G Mann; B Stollmann-Gibbels; E T van't Veer-Korthof; E van Wering; M Zimmermann
Journal:  Blood       Date:  1997-05-15       Impact factor: 22.113

Review 3.  RAS diseases in children.

Authors:  Charlotte M Niemeyer
Journal:  Haematologica       Date:  2014-11       Impact factor: 9.941

4.  Development of T-cell acute lymphoblastic leukemia in a patient in very long lasting complete remission of juvenile myelomonocytic leukemia.

Authors:  Alexei A Maschan; Lili A Khachatrian; Galina G Solopova; Elena Yu Ossipova; Luidmila V Baidun; Svetlana V Dmitrieva; Mikhail A Maschan; Igor B Resnik
Journal:  J Pediatr Hematol Oncol       Date:  2011-01       Impact factor: 1.289

5.  Autoimmune lymphoproliferative syndrome-like disease with somatic KRAS mutation.

Authors:  Masatoshi Takagi; Kunihiro Shinoda; Jinhua Piao; Noriko Mitsuiki; Mari Takagi; Kazuyuki Matsuda; Hideki Muramatsu; Sayoko Doisaki; Masayuki Nagasawa; Tomohiro Morio; Yoshihito Kasahara; Kenichi Koike; Seiji Kojima; Akira Takao; Shuki Mizutani
Journal:  Blood       Date:  2010-11-09       Impact factor: 22.113

6.  Somatic mosaicism for oncogenic NRAS mutations in juvenile myelomonocytic leukemia.

Authors:  Sayoko Doisaki; Hideki Muramatsu; Akira Shimada; Yoshiyuki Takahashi; Makiko Mori-Ezaki; Masanori Sato; Hiroyuki Kawaguchi; Akitoshi Kinoshita; Manabu Sotomatsu; Yasuhide Hayashi; Yoko Furukawa-Hibi; Kiyofumi Yamada; Hideaki Hoshino; Hitoshi Kiyoi; Nao Yoshida; Hirotoshi Sakaguchi; Atsushi Narita; Xinan Wang; Olfat Ismael; Yinyan Xu; Nobuhiro Nishio; Makito Tanaka; Asahito Hama; Kenichi Koike; Seiji Kojima
Journal:  Blood       Date:  2012-07-02       Impact factor: 22.113

7.  Myelodysplastic and myeloproliferative disorders of childhood: a study of 167 patients.

Authors:  S Luna-Fineman; K M Shannon; S K Atwater; J Davis; M Masterson; J Ortega; J Sanders; P Steinherz; V Weinberg; B J Lange
Journal:  Blood       Date:  1999-01-15       Impact factor: 22.113

8.  The novel subset of CD14+/CD16+ blood monocytes is expanded in sepsis patients.

Authors:  G Fingerle; A Pforte; B Passlick; M Blumenstein; M Ströbel; H W Ziegler-Heitbrock
Journal:  Blood       Date:  1993-11-15       Impact factor: 22.113

Review 9.  Paediatric myelodysplastic syndromes and juvenile myelomonocytic leukaemia: molecular classification and treatment options.

Authors:  Charlotte Marie Niemeyer; Christian Peter Kratz
Journal:  Br J Haematol       Date:  2008-03       Impact factor: 6.998

Review 10.  Juvenile myelomonocytic leukemia: molecular pathogenesis informs current approaches to therapy and hematopoietic cell transplantation.

Authors:  Christopher C Dvorak; Mignon L Loh
Journal:  Front Pediatr       Date:  2014-03-28       Impact factor: 3.418

View more
  25 in total

Review 1.  JMML genomics and decisions.

Authors:  Charlotte M Niemeyer
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2018-11-30

2.  T and B cell clonal expansion in Ras-associated lymphoproliferative disease (RALD) as revealed by next-generation sequencing.

Authors:  S Levy-Mendelovich; A Lev; E Rechavi; O Barel; H Golan; B Bielorai; Y Neumann; A J Simon; R Somech
Journal:  Clin Exp Immunol       Date:  2017-06-05       Impact factor: 4.330

3.  Rabex-5 is a lenalidomide target molecule that negatively regulates TLR-induced type 1 IFN production.

Authors:  David Millrine; Mami Tei; Yohannes Gemechu; Tadamitsu Kishimoto
Journal:  Proc Natl Acad Sci U S A       Date:  2016-09-06       Impact factor: 11.205

4.  eRepo-ORP: Exploring the Opportunity Space to Combat Orphan Diseases with Existing Drugs.

Authors:  Michal Brylinski; Misagh Naderi; Rajiv Gandhi Govindaraj; Jeffrey Lemoine
Journal:  J Mol Biol       Date:  2017-12-10       Impact factor: 5.469

Review 5.  Gene mutations do not operate in a vacuum: the increasing importance of epigenetics in juvenile myelomonocytic leukemia.

Authors:  Christian Flotho
Journal:  Epigenetics       Date:  2019-03-08       Impact factor: 4.528

6.  Primary immunodeficiencies: novel genes and unusual presentations.

Authors:  Luigi D Notarangelo; Gulbu Uzel; V Koneti Rao
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2019-12-06

7.  18F-FDG PET Imaging Features of Patients With Autoimmune Lymphoproliferative Syndrome.

Authors:  Jorge A Carrasquillo; Clara C Chen; Susan Price; Millie Whatley; Nilo A Avila; Stefania Pittaluga; Elaine S Jaffe; V Koneti Rao
Journal:  Clin Nucl Med       Date:  2019-12       Impact factor: 7.794

Review 8.  Pediatric Neoplasms Presenting with Monocytosis.

Authors:  Jacob R Greenmyer; Mira Kohorst
Journal:  Curr Hematol Malig Rep       Date:  2021-02-25       Impact factor: 3.952

9.  Sustained remission with azacitidine monotherapy and an aberrant precursor B-lymphoblast population in juvenile myelomonocytic leukemia.

Authors:  Saman K Hashmi; Jyotinder N Punia; Andrea N Marcogliese; Amos S Gaikwad; Kevin E Fisher; Angshumoy Roy; Pulivarthi Rao; Dolores H Lopez-Terrada; Jo Ringrose; Mignon L Loh; Charlotte M Niemeyer; Rachel E Rau
Journal:  Pediatr Blood Cancer       Date:  2019-06-28       Impact factor: 3.167

Review 10.  Turning the tide in myelodysplastic/myeloproliferative neoplasms.

Authors:  Michael W N Deininger; Jeffrey W Tyner; Eric Solary
Journal:  Nat Rev Cancer       Date:  2017-06-23       Impact factor: 60.716

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.